Infliximab or Remicade is useful in the treatment of Crohn's disease refractory to other treatment. It is available as an intravenous product and is used on a short term basis.
Infliximab or Remicade inhibits tumour necrosis factor or TNF in the body. TNF is involved in the production of inflammation, thus by inhibiting it, inflammation is reduced.
Infliximab or Remicade is associated with nausea, chest pain, fever, facial flushing, headache, itch, indigestion, and low blood pressure. These side effects are thought to be related to the infusion rather than the drug itself.
Severe infections and lymphomas have been reported.
Because severe infections and lymphomas have been reported, people who have compromised immune systems may not be suitable candidates. Infliximab or Remicade should not be used by pregnant individuals.
Infliximab or Remicade has been used in combination with other drugs also used for Crohn's disease.
N Engl J Med 1997;337:1029
The relevant product monographs must be regarded as the appropriate sources of prescribing information.